Emmanuel Macron, President of the French Republic, and Bruno Lemaire, Minister of Economy, Finance and Relaunch, present
NEWBURYPORT, MASS., USA
This $35 million (30 million euro) investment in one of the 3 flagship pharmaceutical synthesis technologies demonstrates the SEQENS Group’s ability to design, expand and industrialize the molecules of maximum complexity while maintaining a higher point of functionality in terms of quality.protection and respect for the environment.
This project, called UPP30, carried out in collaboration with the Belgian biotechnology corporation Mithra for the production of a fifth generation contraceptive molecule with a superior protection profile for women and a very high point of biodegradability, which gives it a primary environmental interest.demonstrates the interest of giant pharmaceutical corporations and biotechnology corporations in relying on local and sustainable expertise for the progression and industrialization of their molecules.
“Today, I am proud and pleased to mark the beginning of the fruit of many years of paintings and to see that the SEQENS Group continues to invest heavily in the latest state-of-the-art technologies to maintain and expand more than one hundred years of knowledge and capabilities and, therefore, continue to maintain authentic pharmaceutical synthesis capabilities in France.This is the key to maintaining our long-term fitness sovereignty.”said JeanPhilippe Aubert, assignment manager at SEQENS UPP30.
As a built-in player in the drug production chain, from the production of intermediaries to the production of pharmaceutical active ingredients and from studies and progression to commercialization, SEQENS has the technical and commercial functions to relocate and develop the production capacity of critical molecules.
For SEQENS, the revitalization of our trade footprint will be based on 3 pillars:
Skills development. SEQENS is committed to doubling the number of its academics and apprentices alternately, i.e. in the technical fields, and will do so until the early 2020s.By 2021, more than 150 young people will be welcome to our sites to be informed about our trades.Similarly, SEQENS has established an educational program to provide a qualified career path and radical professional adjustments to others who wish to realize the global industry.
Innovation and R
The quality and functionality of our productions. SEQENS is first and foremost a commercial organization that is based on the maximum competence of its workers in its 24 production plants, it is a commercial culture of functionality, rigor and continuous improvement that allows us to continue to offer our consumers quality products in accordance with the standards of quality, environment and protection.
It is the good fortune of strategic projects such as upP30, one of the most productive services in the world, which promises the maintenance and progression in France from price chains surely to the physical security of our country.
“Our ability to sustain will have the ability of our corporations to innovate and bring productive investment in our territories to life.SEQENS is in a position to take on the challenge through the construction of innovation, the R
SEQENS: SEQENS is a world leader in pharmaceutical synthesis and special ingredients.With 24 production sites and 3 R
Driven by a culture of excellence and a strong entrepreneurial spirit, our 3,200 workers are committed to providing our consumers with a point of service and quality while acting ethically in accordance with our corporate social duty [email protected]/www.seqens.com/ Linkedin: SEQENS / Twitter: seqens_group
Attachments
Emmanuel Macron at SEQENS Opening 2020
Emmanuel Macron and Bruno Lemaire at the opening of SEQENS